Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Translational medicine

Primed for resistance

Nature volume 483, pages 44–45 (2012)Cite this article

Subjects

A drug for treating melanoma is ineffective in colorectal cancers that have the same causative mutation. Studies of how cells adapt to the drug reveal why this is so, and suggest combination therapies that may be more effective. See Letter p.100

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Intrinsic drug resistance in colorectal cancer cells.

References

  1. Chapman, P. B. et al. N. Engl. J. Med. 364, 2507–2516 (2011).

    Article  CAS  Google Scholar 

  2. Kopetz, S. et al. J. Clin. Oncol. 28 (ASCO Meet. Abstr. Pt 1), abstr. 3534 (2010).

  3. Prahallad, A. et al. Nature 483, 100–103 (2012).

    Article  ADS  CAS  Google Scholar 

  4. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. Nature 464, 427–430 (2010).

    Article  ADS  CAS  Google Scholar 

  5. Nazarian, R. et al. Nature 468, 973–977 (2010).

    Article  ADS  CAS  Google Scholar 

  6. Poulikakos, P. I. et al. Nature 480, 387–390 (2011).

    Article  ADS  CAS  Google Scholar 

  7. Corcoran, R. B. et al. Cancer Discov. http://dx.doi.org/10.1158/2159-8290.CD-11-0341 (2012).

  8. Di Nicolantonio, F. et al. J. Clin. Oncol. 26, 5705–5712 (2008).

    Article  CAS  Google Scholar 

  9. Joseph, E. W. et al. Proc. Natl Acad. Sci. USA 107, 14903–14908 (2010).

    Article  ADS  CAS  Google Scholar 

  10. Oberholzer, P. A. et al. J. Clin. Oncol. 30, 316–321 (2012).

    Article  CAS  Google Scholar 

  11. Su, F. et al. N. Engl. J. Med. 366, 207–215 (2012).

    Article  CAS  Google Scholar 

  12. Infante, J. R. et al. J. Clin. Oncol. 29 (ASCO Meet. Abstr. Pt 1), abstr. CRA8503 (2011).

Download references

Author information

Authors and Affiliations

  1. David B. Solit is in the Department of Medicine and the Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.,

    David B. Solit

  2. Pasi A. Jänne is at the Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA.,

    Pasi A. Jänne

Authors
  1. David B. Solit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pasi A. Jänne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to David B. Solit or Pasi A. Jänne.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Solit, D., Jänne, P. Primed for resistance. Nature 483, 44–45 (2012). https://doi.org/10.1038/483044a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/483044a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing